Obalon Balloon System
Commercial- Indications
- Obesity, Weight management
Company intelligence / Profile preview
Obalon Therapeutics developed and commercialized the Obalon Balloon System—a swallowable, gas-filled intragastric balloon designed to facilitate weight loss in obese adults. The system received FDA premarket approval based on a pivotal trial showing approximately double the weight loss compared to sham controls with a strong safety profile. The product was commercially launched in 2017 and was available in select international markets prior to US approval[5][6].
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Obalon Therapeutics.